Evidence map›Paper›PMID 40323106›Full record

ArticlemSphere2025

When passion is not enough: the waning of the infectious disease workforce.

Jennifer A Leeds

Abstract read
In one paragraph

Article in mSphere, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Standing up for Medical Microbiology.Journal of medical microbiology · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Jennifer A LeedsIndependent Consultant, Walnut Creek, California, USA.ORCID 0000-0003-2244-4713

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Scientists and physicians who pursue careers in infectious diseases are often passionate about understanding microbial pathogenesis and anti-microbial resistance. They are driven by the impact that their work has on improving public health and reducing human suffering through the discovery, development, and delivery of technologies that enable prevention and radical cure of debilitating and deadly diseases. Yet, despite their passion, there is a shrinking talent pool in antibiotic research and development (R&D) (https://www.amrindustryalliance.org/mediaroom/leaving-the-lab-tracking-the-decline-in-amr-rd-professionals/) as well as in the clinical practice specialty of infectious diseases as recognized by the Infectious Diseases Society of America (https://www.idsociety.org/news--publications-new/articles/2024/idsa-and-pids-statement-on-2024-id-fellowship-match/). This talent drain has wide repercussions beyond its impact on R&D and clinical practice and needs to be addressed from many angles to attract and retain new talent, to increase investment in and output from antibiotic R&D, and to mitigate the rising risk of the inability to deliver safe and efficacious solutions to patients in need.

Indexed as

Communicable DiseasesPhysiciansWorkforceAnti-Bacterial AgentsHumansAnti-Bacterial Agentsincentivesinfectious diseasestalent

Identifiers

PMID40323106
PMCPMC12108070

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.